NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid • Children’s Health Defense

In response to reports of patients relapsing after taking Paxlovid, Pfizer CEO Albert Bourla on Tuesday suggested they take more of the treatment, contrary to the established protocol.

John Farley, M.D., director of the Office of Infectious Diseases, in the FDA Updates on Paxlovid for Health Care Providers wrote:

“There is no evidence of benefit at this time for a longer course of treatment (e.g., 10 days rather than the 5 days recommended in the Provider Fact Sheet for Paxlovid) or repeating a treatment course of Paxlovid in patients with recurrent COVID-19 symptoms following completion of a treatment course.”

Bloomberg and ABC News reported on accounts of viral rebound after treatment with Paxlovid that were posted on social media or described by physicians and patients.

The FDA in December 2021, granted Emergency Use Authorization (EUA) for Paxlovid, a combination of nirmatrelvir and ritonavir tablets, for patients at high risk of progressing to severe COVID-19.

NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid • Children’s Health Defense

It also helps the Big Pharma monopoly that this patented new ’emergency treatment’ costs over $500 for a five day span, compared to Ivermectin, which is sold over the counter in multiple countries and which is dirt cheap.